Biocardia, INC 10-Q quarterly reports

BioCardia, Inc. reported continued clinical development progress for its cell therapies but highlighted significant going concern issues due to insufficient cash reserves beyond January 2027.

BioCardia, Inc. reported its first quarter 2026 financial results, highlighting ongoing development of its cell therapies and progress with regulatory bodies, while facing significant cash burn and Nasdaq listing concerns.

BioCardia reports significant clinical trial advancements for its cell therapies and delivery systems, alongside ongoing capital raises and a going concern warning.

BioCardia, Inc. reports significant net losses and liquidity challenges, raising substantial doubt about its ability to continue operations beyond October 2025, alongside a Nasdaq non-compliance notice.

BioCardia, Inc. reported significant net losses and a critical cash shortage, raising substantial doubt about its ability to continue operations beyond October 2025, despite ongoing clinical trial progress.

BioCardia's Q1 2025 results reveal a net loss and raise concerns about the company's ability to continue as a going concern without additional funding.

BioCardia's Q3 2024 report highlights progress in clinical trials, a recent capital raise, and ongoing efforts to advance its cell therapy platforms.

BioCardia's Q2 2024 report highlights a decrease in operating expenses and ongoing clinical trial advancements, while also noting substantial doubt about the company's ability to continue as a going concern without additional funding.

BioCardia's Q1 2024 results show a net loss of $2.267 million and raise concerns about the company's ability to continue as a going concern without additional funding.